Page 2 - Virtual Plenary News Today

GSK receives US FDA file acceptance for Jemperli

Results published in The New England Journal of Medicine and presented simultaneously at ESMO Virtual Plenary and SGO Annual Meeting72% and 36% reduction...

Greatest benefit continued to be seen in people who are at a high risk of recurrence (those with lymph node-positive disease)With longer follow-up, treatment effect continues to be seen regardless of hormone

14.07.2022 - Greatest benefit continued to be seen in people who are at a high risk of recurrence (those with lymph node-positive disease)With longer follow-up, treatment effect continues to be seen regardless of hormone receptor status; however overall survival ...

Fisheries and aquaculture still face sustainability challenges, but as trade in the sector continues to grow, its contribution to food security and the safeguarding of livelihoods remains critical, QU Dongyu, Director-General of the Food and Agriculture Organization of the United Nations (FAO), said on Tuesday.

– Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners – –...

Longer-term results from the OlympiA trial show a 32% improvement in overall survival with olaparib among women with early-stage germline BRCA-mutated breast cancer.

NEWTON, Mass. - Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that results from the Phase 3 SIENDO study will be presented at... | March 17, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...